Dual neonate vaccine platform against HIV-1 and M. tuberculosis.

Dual neonate vaccine platform against HIV-1 and M. tuberculosis.

Acquired immunodeficiency syndrome and tuberculosis (TB) are two of the world's most devastating diseases. The first vaccine the majority of infants born in Africa receive is Mycobacterium bovis bacillus Calmette-Guerin (BCG) as a prevention against TB. BCG protects against disseminated disease...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Hopkins, R, Bridgeman, A, Joseph, J, Gilbert, S, McShane, H, Hanke, T
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	Public Library of Science 2011

Gelijkaardige items

Dual neonate vaccine platform against HIV-1 and M. tuberculosis.
door: Richard Hopkins, et al.
Gepubliceerd in: (2011-01-01)

Vaccine strategies against tuberculosis
door: H McShane
Gepubliceerd in: (2009-03-01)

Vaccines for tuberculosis
door: McShane, H
Gepubliceerd in: (2013)

Vaccine Platform for Prevention of Mother-to-Child Transmission of HIV-1 through Breastfeeding
door: Im, E, et al.
Gepubliceerd in: (2008)

Insights and challenges in tuberculosis vaccine development
door: McShane, H
Gepubliceerd in: (2019)

Tuberculosis vaccines: beyond bacille Calmette–Guérin
door: McShane, H
Gepubliceerd in: (2011)

Tuberculosis vaccines: Beyond bacilli Calmette-Guérin
door: McShane, H
Gepubliceerd in: (2011)

Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis
door: Christopher J. De Voss, et al.
Gepubliceerd in: (2025-02-01)

Vaccination against tuberculosis: how can we better BCG?
door: Pitt, J, et al.
Gepubliceerd in: (2013)

Vaccination against tuberculosis: How can we better BCG?
door: Pitt, J, et al.
Gepubliceerd in: (2013)

Tuberculosis vaccines: Progress and challenges
door: Checkley, A, et al.
Gepubliceerd in: (2011)

Vaccine strategies against tuberculosis.
door: Mcshane, H
Gepubliceerd in: (2009)

Developing an improved vaccine against tuberculosis.
door: Mcshane, H
Gepubliceerd in: (2004)

Improving tuberculosis vaccine trial efficiency: a tough nut to crack
door: McShane, H
Gepubliceerd in: (2023)

Why don’t we have an effective tuberculosis vaccine yet?
door: Davenne, T, et al.
Gepubliceerd in: (2016)

Clinical testing of tuberculosis vaccine candidates
door: Hatherill, M, et al.
Gepubliceerd in: (2016)

The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy
door: Vermaak, S, et al.
Gepubliceerd in: (2023)

Replacing, reducing and refining the use of animals in tuberculosis vaccine 1 research
door: Tanner, R, et al.
Gepubliceerd in: (2016)

WHO preferred product characteristics for new vaccines against tuberculosis
door: Schrager, L, et al.
Gepubliceerd in: (2018)

Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.
door: Im, E, et al.
Gepubliceerd in: (2007)

Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?
door: Dockrell, HM, et al.
Gepubliceerd in: (2022)

Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice
door: Griffiths, K, et al.
Gepubliceerd in: (2013)

Construction and characterization of recombinant MTBVAC. HIV, a new live attenuated vaccine against HIV and tuberculosis
door: Saubi, N, et al.
Gepubliceerd in: (2018)

Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
door: Hazel M. Dockrell, et al.
Gepubliceerd in: (2022-05-01)

Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle
door: Villarreal-Ramos, B, et al.
Gepubliceerd in: (2017)

Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis.
door: Sander, C, et al.
Gepubliceerd in: (2007)

Human and Bovine Tuberculosis
door: McShane, H
Gepubliceerd in: (2016)

MTBVAC-based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in Mice
door: Broset, E, et al.
Gepubliceerd in: (2019)

Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine.
door: Bridgeman, A, et al.
Gepubliceerd in: (2009)

MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice
door: Esther Broset, et al.
Gepubliceerd in: (2019-06-01)

Identification of antigens presented by MHC for vaccines against tuberculosis
door: Bettencourt, P, et al.
Gepubliceerd in: (2020)

Identification of antigens presented by MHC for vaccines against tuberculosis
door: Bettencourt, P, et al.
Gepubliceerd in: (2020)

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges
door: Stylianou, E, et al.
Gepubliceerd in: (2019)

Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines.
door: Dean, G, et al.
Gepubliceerd in: (2014)

MVA as a vector for vaccines against HIV-1.
door: Im, E, et al.
Gepubliceerd in: (2004)

Engineering a dual vaccine against COVID-19 and tuberculosis
door: Carlyn Monèt Guthrie, et al.
Gepubliceerd in: (2023-10-01)

Controlled human infection models: is it really feasible to give people tuberculosis?
door: McShane, H
Gepubliceerd in: (2020)

Local pulmonary immunological biomarkers in tuberculosis
door: Morrison, H, et al.
Gepubliceerd in: (2021)

Local Pulmonary Immunological Biomarkers in Tuberculosis
door: Hazel Morrison, et al.
Gepubliceerd in: (2021-03-01)

Tuberculosis vaccines in clinical trials.
door: Rowland, R, et al.
Gepubliceerd in: (2011)